M. Kjellin, T. Wesslén, E. Löfblad, J. Lennerstrand, and A. Lannergård, “The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort”, ujms, vol. 123, no. 1, pp. 50–56, Mar. 2018.